• 1. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 2. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 3. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 4. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 5. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932

Professional Introduction to (S)-1-Ethyl-3-methyl-piperazine Dihydrochloride (CAS No. 1630082-91-5)

(S)-1-Ethyl-3-methyl-piperazine dihydrochloride, identified by its CAS number 1630082-91-5, is a significant compound in the field of pharmaceutical chemistry and drug development. This chiral piperazine derivative has garnered considerable attention due to its versatile applications in medicinal chemistry and its potential in the synthesis of various bioactive molecules. The compound's unique structural and stereochemical properties make it a valuable intermediate in the creation of pharmacologically relevant molecules, particularly those targeting neurological and cardiovascular systems.

The stereochemistry of (S)-1-Ethyl-3-methyl-piperazine dihydrochloride plays a crucial role in determining its biological activity. As a enantiomer, the (S)-configuration confers specific interactions with biological targets, which can significantly influence the efficacy and selectivity of drug candidates. Recent advancements in computational chemistry and molecular modeling have enabled researchers to better understand how the spatial arrangement of atoms in this compound affects its pharmacokinetic and pharmacodynamic profiles. These insights are particularly valuable in the design of next-generation therapeutics that require high precision in target binding.

In recent years, there has been a surge in research focused on developing novel treatments for neurological disorders, such as depression, anxiety, and schizophrenia. The piperazine scaffold, a key structural feature of (S)-1-Ethyl-3-methyl-piperazine dihydrochloride, is widely recognized for its ability to modulate neurotransmitter systems. Studies have demonstrated that derivatives of this compound can interact with serotonin receptors, leading to potential therapeutic benefits. For instance, modifications to the ethyl and methyl substituents on the piperazine ring can fine-tune receptor binding affinity, offering a pathway to develop more effective and safer medications.

The dihydrochloride salt form of this compound enhances its solubility in aqueous solutions, making it more suitable for formulation into injectable or oral medications. This property is particularly important in drug development, where bioavailability and pharmacokinetic behavior are critical factors. The improved solubility also facilitates advanced delivery systems, such as nanoparticles and liposomes, which can enhance drug delivery efficiency and target specificity.

Current research is exploring the use of (S)-1-Ethyl-3-methyl-piperazine dihydrochloride as a building block for more complex molecules. By incorporating this compound into larger scaffolds, chemists can create novel compounds with enhanced biological activity. For example, recent studies have shown promising results in using this derivative as a precursor for antipsychotic agents. The ability to modify specific functional groups while maintaining the core piperazine structure allows for extensive chemical diversity, enabling the discovery of new therapeutic entities.

The synthesis of (S)-1-Ethyl-3-methyl-piperazine dihydrochloride involves multi-step organic reactions that require precise control over reaction conditions. Advanced synthetic methodologies, such as asymmetric catalysis and enantioselective hydrogenation, are employed to ensure high enantiomeric purity. These techniques not only improve yield but also reduce the environmental impact of drug production by minimizing waste generation.

In clinical settings, the use of this compound has shown promise in preclinical trials for various therapeutic applications. Its ability to modulate neurotransmitter activity makes it a candidate for treating conditions associated with imbalances in these systems. While further research is needed to fully understand its potential benefits and risks, early findings suggest that derivatives of this compound could offer significant advantages over existing treatments.

The pharmaceutical industry continues to invest heavily in research aimed at optimizing the properties of (S)-1-Ethyl-3-methyl-piperazine dihydrochloride. By leveraging cutting-edge technologies such as high-throughput screening and artificial intelligence-driven drug design, scientists are identifying new applications for this versatile compound. These efforts are expected to lead to the development of innovative therapies that address unmet medical needs.

In conclusion, (S)-1-Ethyl-3-methyl-piperazine dihydrochloride (CAS No. 1630082-91-5) represents a promising area of research with significant implications for drug development. Its unique structural features and stereochemical properties make it a valuable tool for creating novel bioactive molecules. As our understanding of its pharmacological effects continues to grow, so too does its potential to contribute to advancements in medicine.

• 1152110-26-3((R)-1,3-Dimethylpiperazine dihydrochloride)
• 1195782-28-5(cis-1,2,6-trimethylpiperazine;dihydrochloride)
• 1022094-05-8(1,3-Dimethylpiperazine hydrochloride)
• 1046788-71-9((2R,5s)-1,2,5-trimethylpiperazine hydrochloride)
• 485841-50-7((2S)-1,2-dimethylpiperazine dihydrochloride)
• 1152110-30-9((3S)-1,3-dimethylpiperazine;dihydrochloride)
• 884199-34-2(1-Isopropyl-(S )-2-methylpiperazine dihydrochloride)
• 1152110-23-0((2R)-1,2-Dimethylpiperazine dihydrochloride)
• 1630082-92-6((R)-1-Ethyl-3-methyl-piperazine dihydrochloride)
• 799557-83-8(Piperazine, 2-methyl-1-(1-methylethyl)-, hydrochloride, (2S)-)